Immunity 12 years after alemtuzumab in RA: Cd5 + b-cell depletion, thymus-dependent t-cell reconstitution and normal vaccine responses

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1397-1406

  Anderson, Amy E ^a   Lorenzi, Alice R ^a,b   Pratt, Arthur ^a,b   Wooldridge, Tom ^a,b   Diboll, Julie ^a   Hilkens, Catharien M U ^a   Isaacs, John D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alemtuzumab; CD5+ B cells; Immune reconstitution; Rheumatoid arthritis; Thymic function; Vaccine responses

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; CD45RA ANTIGEN; CD5 ANTIGEN; DIPHTHERIA TOXOID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; L SELECTIN; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; AGING; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; MEMORY CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROCONVERSION; SEROLOGY; SIDE EFFECT; SURVIVAL; THYMUS; TREATMENT RESPONSE; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD5; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNITY; IMMUNOPHENOTYPING; INFLUENZA VACCINES; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOPENIA; MALE; MIDDLE AGED; T-LYMPHOCYTES; THYMUS GLAND;

EID: 84865174206     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes038     Document Type: Article

References (46)

1. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82:807-12.
2. Isaacs JD, Greer S, Sharma S et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001;44:1998-2008.
3. Lorenzi AR, Clarke AM, Wooldridge T et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum 2008;58:370-5.
4. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
5. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
6. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86.
7. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
8. Gelinck LB, Teng YK, Rimmelzwaan GF et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007;66:1402-3.
9. Oren S, Mandelboim M, Braun-Moscovici Y et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-41.
10. Lorenzi AR, Patterson AM, Pratt A et al. Determination of thymic function directly from peripheral blood: a validated modification to an established method. J Immunol Methods 2008;339:185-94.
11. Gary-Gouy H, Harriague J, Bismuth G et al. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002;100:4537-43.
12. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009;8:349-53.
13. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006;5:403-8.
14. Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. Science 1987;236:81-3.
15. Dauphinee M, Tovar Z, Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum 1988; 31:642-7.
16. Youinou P, Mackenzie L, Katsikis P et al. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 1990;33: 339-48.
17. Hassan J, Yanni G, Hegarty V et al. Increased numbers of CD5+ B cells and T cell receptor (TCR) gamma delta+ T cells are associated with younger age of onset in rheumatoid arthritis (RA). Clin Exp Immunol 1996;103: 353-6.
18. Bohm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother 2004;58: 338-43.
19. Nicoletti F, Meroni PL, Barcellini W et al. Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. Immunol Lett 1990;23:211-5.
20. Munoz A, Gallart T, Vinas O, Gomis R. Increased CD5-positive B lymphocytes in type I diabetes. Clin Exp Immunol 1991;83:304-8.
21. Iwatani Y, Amino N, Kaneda T et al. Marked increase of CD5 + B cells in hyperthyroid Graves' disease. Clin Exp Immunol 1989;78:196-200.
22. Afeltra A, Paggi A, Ferri GM et al. CD5+ B lymphocytes and CD4+ CD45RA+ T cells in Graves' disease. Endocr Res 1993;19:73-85.
23. Corrales JJ, Orfao A, Lopez A et al. CD5+ B cells in Graves' disease: correlation with disease activity. Hormone Metab Res 1996;28:280-5.
24. Mix E, Olsson T, Correale J et al. B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol 1990;79:21-7.
25. Seidi OA, Semra YK, Sharief MK. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol 2002;133:205-10.
26. Murakami M, Yoshioka H, Shirai T, Tsubata T, Honjo T. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int Immunol 1995;7:877-82.
27. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987;236:77-81.
28. Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin Immunol Immunopathol 1990;56: 219-25.
29. De Rycke L, Verhelst X, Kruithof E et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302.
30. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
31. Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005;7:R714-24.
32. Cambridge G, Stohl W, Leandro MJ et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32.
33. Teng YK, Levarht EW, Hashemi M et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
34. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74.
35. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-32.
36. Ponchel F, Morgan AW, Bingham SJ et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002;100:4550-6.
37. Koetz K, Bryl E, Spickschen K et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:9203-8.
38. Ponchel F, Verburg RJ, Bingham SJ et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther 2005;7: R80-92.
39. Chidgey A, Dudakov J, Seach N, Boyd R. Impact of niche aging on thymic regeneration and immune reconstitution. Semin Immunol 2007;19:331-40.
40. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
41. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61.
42. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
43. Rose GW, Cooper CL. Fluarix, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006;6:301-10.
44. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
45. van Assen S, Holvast A, Benne CA et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81.
46. Bingham CO 3rd, Looney RJ, Deodhar A et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.